SOURCE: PURE Bioscience, Inc

Pure Bioscience, Inc

September 01, 2015 08:36 ET

PURE Bioscience to Present at Rodman & Renshaw's 2015 Annual Global Investment Conference on September 9th

SAN DIEGO, CA--(Marketwired - Sep 1, 2015) -  PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today the Company will present at Rodman & Renshaw's 2015 Annual Global Investment Conference on Wednesday, September 9, 2015 at the St. Regis Hotel, NY.

Hank R. Lambert, CEO, will present on Wednesday, September 9th at 4:40pm EDT. Lambert will

  • Review progress of the commercialization of SDC as a food safety solution, and
  • Discuss the status of the recent resubmission of its Food Contact Notification (FCN) with the FDA for SDC antimicrobial use in raw poultry processing -- and the status of the pending resubmission for produce processing.
    • SDC test results demonstrate materially significant reduction in Salmonella contamination in poultry -- and materially significant reduction in Salmonella, Listeria and E. coli contamination in produce.

The presentation will be webcast live with slides (and available for replay) and can be accessed on the Company's website, http://www.purebio.com/investors/events-presentations/.

About Rodman & Renshaw
The Rodman & Renshaw Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, is held on September 8 through September 10, 2015 at the St. Regis Hotel in New York. More than 200 public & private companies from around the world are expected to present to an audience of over 2,000 attendees. The event will feature tracks devoted to Biotechnology/Healthcare, Metals & Mining, Technology, Cleantech and Growth. The Conference will include corporate presentations and Q&A sessions, investor one-on-one meetings and daily networking opportunities. 

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements; the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including acceptance of the Company's PURE Hard Surface disinfectant by SUBWAY® franchisees; and the ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw poultry processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including Forms 10-Q and 10-K. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact Information

  • Contacts:
    Hank Lambert
    CEO
    PURE Bioscience, Inc.
    619-596-8600 ext.103
    Email Contact

    Terri MacInnis
    VP of IR
    Bibicoff + MacInnis, Inc.
    818-379-8500
    Email Contact

    Tom Hemingway
    Redwood Investment Group
    714-978-4425
    Email Contact